- Tevogen Bio Holdings (Nasdaq: TVGN) showcased its AI technology at the AI x Bio Philly event.
- Mittul Mehta, CIO of Tevogen.AI, emphasized the use of AI in developing precision T cell therapies.
- The event gathered leaders in AI and biotechnology for discussions on future developments.
Tevogen Bio Holdings (Nasdaq: TVGN), a prominent player in the biotechnology sector, took center stage at the AI x Bio Philly event, a gathering that shines a spotlight on the convergence of artificial intelligence and life sciences in the Philadelphia region. This event, hosted by renowned organizations such as BioBuzz, BitsInBio, Atria, and Zetta, drew innovators, entrepreneurs, and investors to explore the transformative role AI is playing in the biotechnology landscape.
Mittul Mehta, CIO and Head of Tevogen.AI, presented alongside top industry figures, including Irene Rombell of BioCurie, David Latshaw II of BioPhy AI, and Nathan Buchbinder of Proscia. Mehta's presentation showcased Tevogen.AI's proprietary artificial intelligence technology designed to accelerate the discovery and development of off-the-shelf precision T cell therapies. By leveraging computational modeling, Tevogen.AI predicts T cell receptor (TCR) engagement with immunologically active HLA+ peptide complexes, a breakthrough aimed at addressing significant unmet needs in treating infectious diseases and cancers.
Tevogen Bio, known for its specialty in immunotherapy, is advancing the frontier of personalized medicine with its genetically unmodified precision T cell therapies powered by CD8+ cytotoxic T lymphocytes. The company's leadership emphasizes sustainability and patient accessibility, backed by recent positive safety data from clinical trials and a robust intellectual property portfolio including several granted and pending patents, some specifically related to AI.
